RECRUITING

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Description

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

Conditions

HIV-1-infection
Talk to us

Related Conditions:

HIV-1-infection

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Condition
HIV-1-infection
Intervention / Treatment

-

Contacts and Locations

San Diego

University of California, San Diego AntiViral Research Center CRS, San Diego, California, United States, 92103

Atlanta

Ponce de Leon Center CRS, Atlanta, Georgia, United States, 30308

Chicago

Northwestern University CRS, Chicago, Illinois, United States, 60611

Boston

Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States, 02114

Saint Louis

Washington University Therapeutics CRS, Saint Louis, Missouri, United States, 63110

New York

Columbia Physicians & Surgeons CRS, New York, New York, United States, 10032

Chapel Hill

Chapel Hill CRS, Chapel Hill, North Carolina, United States, 27599

Greensboro

Greensboro CRS, Greensboro, North Carolina, United States, 27401

Cincinnati

Cincinnati CRS, Cincinnati, Ohio, United States, 45267

Columbus

Ohio State University CRS, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    National Institute of Allergy and Infectious Diseases (NIAID),

    Sharon Riddler, MD, MPH, STUDY_CHAIR, University of Pittsburgh

    Study Record Dates

    2029-08-01